12th November 2025, Bengaluru: IOL Chemicals and Pharmaceuticals Ltd (IOLCP), a leading manufacturer of pharmaceutical APIs and specialty chemicals, has announced its unaudited financial results for the quarter and half year ended 30th September 2025.
Standalone Q1 FY26 Financial Highlights (₹ in Crore)
| Particulars | Q2 FY26 | Q2 FY25 | Y-o-Y | H1 FY26 | H1 FY25 |
| Total Income | 567.5 | 525.8 | 7.2% | 1,119.2 | 1,028.1 |
| EBITDA | 64.0 | 48.0 | 33.3% | 133.5 | 106.2 |
| EBITDA Margin (%) | 11.1% | 9.0% | +212 bps | 11.8% | 10.2% |
| PAT | 30.0 | 19.2 | 5c.7% | 64.0 | 48.8 |
| PAT Margin (%) | 5.2% | 3.6% | +1c2 bps | 5.6% | 4.7% |
Business and Operational Highlights
- Received EDQM’s Certificate of Suitability for Pantoprazole Sodium Sesquihydrate Process-III on 14th October 2025, enabling exports to Europe and CEP-compliant markets. Pantoprazole sodium is a proton pump inhibitor (PPI) that reduces stomach acid and is used to treat conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger- Ellison syndrome.
- Incorporated IOL Pharmaxis UK Limited in October 2025 to strengthen international operations in Pharmaceuticals and Chemicals business and expanding its global reach
Commenting on the performance, Mr Vikas Gupta, Joint Managing Director said, “Ǫ2 FY2c reflects IOL’s continued operational strength and strategic focus, with revenue from operations rising 7.S% and EBITDA improving 33.3% year-on-year. Importantly, EBITDA margin improved to 11.1% from S.1%, driven by better operating leverage and cost efficiencies. Profit After Tax increased 5c.7% year-on-year with PAT margin expanding to 5.2% from 3.c%, underscoring the strength of our integrated model. However, PAT was marginally impacted on a sequential basis due to higher fuel costs, following the Punjab floods, which temporarily disrupted supply chains and elevated energy inputs. Both our Pharmaceuticals and Chemicals segments reported YoY EBIT growth, reflecting improved operating discipline and recovery in volumes. The Pharmaceuticals segment continues to gain momentum, led by strong traction in non-Ibuprofen APIs. We also incorporated IOL Pharmaxis UK Limited, a strategic step to strengthen our international operations and improve customer proximity in key regions. In the Chemicals segment, we are witnessing steady volume recovery, even as pricing remains under pressure. Going ahead, our focus remains on cost optimisation, process discipline, and maintaining a balanced product mix across end-use sectors.”
